64
Pharma & HealthcareBuy
Mirae Asset Healthcare
Mirae Asset · Direct–Growth · rank #6 of 19 by Smart Score
Data updated
Trailing returns
1 Year
13.9%
+18.6% vs index
3 Years
21.3%
+11.9% vs index
5 Years
14.6%
+6.7% vs index
Since launch
21.3%
Year-by-year performance
2021
+28.6%-2.1% vs index
2022
-10.5%-14.3% vs index
2023
+36.1%+9.5% vs index
2024
+41.2%+25.6% vs index
2025
-2.0%-9.7% vs index
2026
+16.0%+22.0% vs index
Why this score
Mirae Asset Healthcare scores 64/100 — #6 of 19 Pharma & Healthcare fund (Buy). It stands out for 3y return and expense ratio — beating 71% of peers on 3y return. It has no major weak spot vs the category.
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return21.26% · 71st percentile in category
Expense ratio0.62% · 92nd percentile in category
Sharpe ratio0.96 · 69th percentile in category
5Y return14.56% · 61st percentile in category
Sortino ratio1.47 · 77th percentile in category
Fund size3494.44 Cr · 71st percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd10.15%
2.Divi's Laboratories Ltd9.79%
3.Torrent Pharmaceuticals Ltd6.8%
4.Apollo Hospitals Enterprise Ltd5.62%
5.Laurus Labs Ltd5.51%
29 disclosed equity positions · portfolio as of Sept 2026 · weights are % of total corpus.